Clinical trials update from the American Heart Association meeting: ACORN‐CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A‐HeFT, GEMINI, vitamin E meta‐analysis, ESCAPE, CARP, and SCD‐HeFT cost‐effectiveness study

[1]  A. Louis,et al.  A systematic review of telemonitoring for the management of heart failure , 2003, European journal of heart failure.

[2]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[3]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[4]  I. S. Virk,et al.  Combination of Isosorbide Dinitrate and Hydralazine in Blacks With Heart Failure , 2005 .

[5]  G. Freeman,et al.  Long-Term Healthcare and Cost Outcomes of Disease Management in a Large, Randomized, Community-Based Population With Heart Failure , 2004, Circulation.

[6]  B. Massie,et al.  Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. , 1983, Journal of the American College of Cardiology.

[7]  P. Poole‐Wilson,et al.  A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community , 2000, European journal of heart failure.

[8]  F. Rodríguez‐Artalejo,et al.  The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. , 2004, European heart journal.

[9]  U. de Faire,et al.  Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy , 2001, Hypertension.

[10]  N. Freemantle,et al.  Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failure , 2004, European journal of heart failure.

[11]  Anne L. Taylor,et al.  African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. , 2002, Journal of cardiac failure.

[12]  M. Drazner,et al.  Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. , 2002, Journal of the American College of Cardiology.

[13]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[14]  M. Metra,et al.  Efficacy and tolerability of the long‐term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus , 2003, European journal of heart failure.

[15]  M. Acker,et al.  Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. , 2004, Journal of cardiac failure.

[16]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[17]  J. Refsgaard,et al.  Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure , 2000, European journal of heart failure.

[18]  Thomas E. Moritz,et al.  Prophylactic coronary artery revascularization for elective vascular surgery: study design. Veterans Affairs Cooperative Study Group on Coronary Artery Revascularization Prophylaxis for Elective Vascular Surgery. , 1999, Controlled clinical trials.

[19]  Thomas E. Moritz,et al.  Disparate opinions regarding indications for coronary artery revascularization before elective vascular surgery. , 2003, The American journal of cardiology.

[20]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[21]  V. Hasselblad,et al.  Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. , 2001, American heart journal.

[22]  R. Doughty,et al.  Uptake of self‐management strategies in a heart failure management programme , 2003, European journal of heart failure.

[23]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[24]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[25]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[26]  C. Yancy,et al.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.